Related Experiment Videos
Hypericin-an inhibitor of proteasome function.
F Pajonk1, J Scholber, B Fiebich
1Clinical and Experimental Radiation Biology Research Section, Department of Radiation Oncology, University of Freiburg Medical School, 79106 Freiburg, Germany. pajonk@uni-freiburg.de
Cancer Chemotherapy and Pharmacology
|January 27, 2005
Summary
Hypericin, found in Saint John's wort, inhibits proteasome function and impacts NF-kappaB signaling. This suggests potential new therapeutic mechanisms beyond its known antidepressant and radiosensitizing effects.
Area of Science:
- Molecular Biology
- Pharmacology
- Cancer Research
Background:
- Hypericin, the active compound in Saint John's wort, is used for depression and by cancer patients undergoing radiation.
- Hypericin exhibits anti-cancer properties, including apoptosis induction and radiosensitization, but its mechanisms are unclear.
- Potential roles in inflammation and phototoxicity are also noted, highlighting the need for mechanistic studies.
Purpose of the Study:
- To investigate the inhibitory effects of hypericin on proteasome function and associated cellular pathways.
- To explore the impact of hypericin on the NF-kappaB signaling pathway.
- To elucidate the molecular mechanisms underlying hypericin's biological activities.
Main Methods:
- U373 human glioma cells and MCF-7 cells were treated with varying concentrations of hypericin.
- Proteasome activities were measured using fluorogenic peptide assays.
- NF-kappaB activity, transcription factor levels (p65, p50), IkappaBalpha, and caspase-3 were analyzed via EMSA and Western blotting.
Main Results:
- Hypericin demonstrated dose-dependent, photoactivation-independent inhibition of proteasome activity.
- Hypericin treatment suppressed NF-kappaB activity, increased phosphorylated IkappaBalpha, decreased p50 levels, and induced p65 cleavage in U373 cells.
- These effects were observed in MCF-7 cells at higher concentrations, and NF-kappaB inhibition was partially mediated by caspase activation.
Conclusions:
- Hypericin inhibits proteasome function and modulates NF-kappaB signaling in cancer cells.
- The observed effects on NF-kappaB are not solely proteasome-dependent and may involve caspase activation.
- These findings provide insights into hypericin's mechanisms of action, potentially relevant for cancer therapy.